Alpha - Antitrypsin Deficiency - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Alpha - Antitrypsin Deficiency - Pipeline Review, Q2 2011', provides an overview of the Alpha - Antitrypsin Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Alpha - Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha - Antitrypsin Deficiency. 'Alpha - Antitrypsin Deficiency - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Reasons to buy
Summary
Global Markets Direct’s, 'Alpha - Antitrypsin Deficiency - Pipeline Review, Q2 2011', provides an overview of the Alpha - Antitrypsin Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Alpha - Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha - Antitrypsin Deficiency. 'Alpha - Antitrypsin Deficiency - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Alpha - Antitrypsin Deficiency.
- A review of the Alpha - Antitrypsin Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alpha - Antitrypsin Deficiency pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Alpha - Antitrypsin Deficiency.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alpha - Antitrypsin Deficiency pipeline depth and focus of Alpha - Antitrypsin Deficiency therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Alpha- Antitrypsin Deficiency Overview
Therapeutics Development
An Overview of Pipeline Products for Alpha- Antitrypsin Deficiency
Alpha- Antitrypsin Deficiency Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Alpha- Antitrypsin Deficiency Therapeutics - Products under Development by Companies
Companies Involved in Alpha- Antitrypsin Deficiency Therapeutics Development
Talecris Biotherapeutics Holdings Corp
Kamada Ltd.
Applied Genetic Technologies Corporation
Alpha- Antitrypsin Deficiency - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Alpha1-Proteinase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aerosolized AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha1-Proteinase Inhibitor-Aerosol Delivery - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV1-CB-hAAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha- Antitrypsin Deficiency Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 26
LIST OF TABLES
Number of Products Under Development for Alpha- Antitrypsin Deficiency, Q2 2011
Products under Development for Alpha- Antitrypsin Deficiency – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Talecris Biotherapeutics Holdings Corp, 2011
Kamada Ltd., 2011
Applied Genetic Technologies Corporation, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Alpha- Antitrypsin Deficiency Therapeutics – Drug Profile Updates 24
LIST OF FIGURES
Number of Products under Development for Alpha- Antitrypsin Deficiency, Q2 2011
Products under Development for Alpha- Antitrypsin Deficiency – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011 19
Global Markets Direct Report Coverage
Alpha- Antitrypsin Deficiency Overview
Therapeutics Development
An Overview of Pipeline Products for Alpha- Antitrypsin Deficiency
Alpha- Antitrypsin Deficiency Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Alpha- Antitrypsin Deficiency Therapeutics - Products under Development by Companies
Companies Involved in Alpha- Antitrypsin Deficiency Therapeutics Development
Talecris Biotherapeutics Holdings Corp
Kamada Ltd.
Applied Genetic Technologies Corporation
Alpha- Antitrypsin Deficiency - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Alpha1-Proteinase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aerosolized AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha1-Proteinase Inhibitor-Aerosol Delivery - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV1-CB-hAAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha- Antitrypsin Deficiency Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 26
LIST OF TABLES
Number of Products Under Development for Alpha- Antitrypsin Deficiency, Q2 2011
Products under Development for Alpha- Antitrypsin Deficiency – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Talecris Biotherapeutics Holdings Corp, 2011
Kamada Ltd., 2011
Applied Genetic Technologies Corporation, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Alpha- Antitrypsin Deficiency Therapeutics – Drug Profile Updates 24
LIST OF FIGURES
Number of Products under Development for Alpha- Antitrypsin Deficiency, Q2 2011
Products under Development for Alpha- Antitrypsin Deficiency – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011 19
